Ignite Creation Date:
2025-12-24 @ 7:48 PM
Ignite Modification Date:
2025-12-25 @ 5:25 PM
Study NCT ID:
NCT03483103
Status:
COMPLETED
Last Update Posted:
2023-12-20
First Post:
2018-03-23
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Sponsor:
Juno Therapeutics, a Subsidiary of Celgene
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-07-27
Start Date Type:
ACTUAL
Primary Completion Date:
2021-09-24
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-01
Completion Date Type:
ACTUAL
First Submit Date:
2018-03-23
First Submit QC Date:
None
Study First Post Date:
2018-03-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-09-23
Results First Submit QC Date:
None
Results First Post Date:
2022-12-29
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-28
Last Update Post Date:
2023-12-20
Last Update Post Date Type:
ACTUAL